Treatment with Atyr Pharma’s efzofitimod, known as EFZO-FIT for short, led to improvements in general health-related quality of life…
Articles by Lindsey Shapiro, PhD
The Foundation for Sarcoidosis Research (FSR) has awarded $450,000 to three scientists to support research projects related to…
Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod —…
The National Organization for Rare Disorders (NORD) is seeking participants for its survey-based study Living Rare, which aims to…
Autoimmune responses against healthy proteins in the retina, which is the back of the eye, could play a role in…
The Foundation for Sarcoidosis Research (FSR) has granted $300,000 in funding to support three scientists embarking on research studies…
Among cardiac sarcoidosis (CS) patients treated with immunosuppressants, those with heart involvement alone can have poorer clinical outcomes than…
Among people with sarcoidosis who failed to respond to earlier lines of treatment, the use of abatacept or tofacitinib…
The activation of signaling pathways associated with immune B-cells may be a key feature that distinguishes sarcoidosis from tuberculosis,…
Involvement of the pericardium, a sac-like membrane that surrounds and protects the heart, is an uncommon manifestation of cardiac…